Brought to you by 
TyRx Pharma gets $25mm through its Series E round
25 Sep 2020
Executive Summary
TyRx Pharma (drug-eluting devices) has raised $25mm through the closing of its Series E venture round. Clarus Ventures and Pappas Ventures co-led the financing and will each gain representation on the company's board. TyRx will use the money to launch its recently FDA-cleared AIGISrx, an implantable device that holds a pacemaker or implantable cardioverter defibrillator in place and contains the antibacterial compounds rifampin and minocycline to lower the risk of infections.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Medical Devices
- Biomaterials
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TyRx Pharma gets $25mm through its Series E round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice